Tag: development

Companies belonging to the Arco Vara group are launching the construction of two new residential real estate development projects in Tallinn.

MONTREAL, June 30, 2025 (GLOBE NEWSWIRE) -- Dorel Industries Inc. (TSX: DII.B, DII.A) is providing a business update on its on-going operations as promised in its first quarter financial results press release issued on May 12, 2025.

The Company is announcing a strategic shift in its operations with a significant reduction in the size of its Home segment which is expected to return the segment to profitability in 2026. These changes will be facilitated by a reduced product line focusing on profitable categories and the elimination of the domestic manufacturing operations based in Cornwall, Ontario.

As described in the first quarter earnings release, Dorel Home initiated a new round of restructuring in the second quarter founded upon the reduction of the size of the organization and its ability to merge the sales, marketing and product development organization into the successful Cosco division. A limited number of high-performing Dorel Home import SKUs will be transferred to the Cosco portfolio, focused on categories and customers driving the highest contribution with the least added complexity.

Cosco has delivered consistent earnings and positive cash flow within the Home segment since 2010, including the period in which it was led by Troy Franks, current CEO of Dorel Home. The organization is built on a market-driven, customer centric approach that delivers innovative products with exceptional consumer value. For over 90 years, Cosco has been a trusted household brand known for reliable performance and quality.

The sale of the 2025 45X Tax Credits supports Heliene’s ongoing workforce and manufacturing growth in Minnesota, enhancing job security and long-term sustainability across local communities.

FORT WORTH, Texas, June 30, 2025 (GLOBE NEWSWIRE) -- HighPeak Energy, Inc. (“HighPeak” or the “Company”) (NASDAQ: HPK) today announced that it intends to offer, subject to market and customary conditions, $725 million aggregate principal amount of senior notes due 2030 (the “Notes”) in a private placement under Rule 144A and Regulation S of the Securities Act of 1933, as amended (the “Securities Act”), to eligible purchasers (the “Offering”).

CAMBRIDGE, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to tacrolimus in adults diagnosed with primary membranous nephropathy (PMN). PROMINENT is designed to enroll approximately 180 adults with PMN and expected to readout in 2029. PMN is a severe antibody-mediated disease of the kidney that is a leading cause of nephrotic syndrome and carries a significant risk of kidney failure.